NNVC NanoViricides Inc

$NNVC this stock is going back to .85 lows. I thought Ebola trial start was going to be announced this week? I don’t understand how retail doesn’t see through this pump and dump. 25 years without revenue. What makes you think they magically figured it out?

$NNVC News out they have been dosing Ebola since the 23. From last week. Exciting news. Both trials are running simultaneously.

$NNVC every day the stock goes up a few pennies and a penny suckers jump in and make a couple hundred bucks and goes down and they think they’re getting rich so they can go buy McDonald’s hamburger 

$NNVC: Be advised that there is a regulatory requirement that Nano cannot release any information about the Phase 2A Ebola efficacy trial (in Ituri Province, DRC) until it has completed the 20 patient enrollment and then 28 days have elapsed with the last patient post-admission. Dr. Diwan (Anil) is hopeful that the benefits of even 3 days of Oral Gummies melting on a patient's tongue, with the release of billions of nanoviricdes in the bloodstream each of those mornings, enveloping the virus particles and killing them, will show such improvement in each patient' health that enrollment will be speeded up and the 28 day wait-time for the last of the 20 being dosed will be dramatically shortened. Let's hope so!

$NNVC the only way to get drugs effectively delivered to 3rd world countries is not by injection, nor swallowing pill Chewy gummies. If effective this would be absolutely the drug of choice 30$ stock

$NNVC: NV-387, the Nano therapeutic being used in the Congo Ebola Phase II trial, not only will work, but I suspect all the patients will be cured within 12 days from the start of administration, although the trial is slated to last 30 days, if more is needed. Dosing is one Gummy each morning placed carefully on the tongue and simply allowed to dissolve, which will release BILLIONS of nanoviricides to circulate in the bloodstream and being the same size as the virus particle, will fake out that particle into thinking it is entering a human cell, encapsulate it, and kill it. Dr Diwan has spent 34 years on this invention, which will earn him the Nobel Prize for Medicine, and when trial results are PRed, will send NNVC into the stratosphere.

$NNVC IMO... MORE TO COME... announcement of commencement of Dosing for Phase II Trials....EBOLA in Democratic Republic of Congo ...will catapult first to $1.80 then to $2.00 by end of week... Predicting 25% more upside this week over $1.60... to $2.00 all IMO.

$NNVC - Looks like somebody is optimistic that the Ebola trial might actually get started. Solid early trading day volume and a solid 14% gain are welcome things to see.

$NNVC The drug NV-387 isn't just an Ebola treatment, however. It is a broad-spectrum antiviral that works perfectly on 90% of all known viruses, some of which like COVID and RSV have enormous markets and therefore are far more lucrative. Thus I envision the separate out-licensing of each viral indication in a bidding process that will continue for years to come,as each virus is cured, making the current stock market valuation of $36 million the most undervalued I have ever known in my 60 years of investing ONLY in one stock at a time.

$NNVC any good, successful company is like anything else…moderna pfizer etc. $NNVC will prove itself and climb and climb and climb, maybe get bought out. Bears will be bears just like moderna pfizer etc have their days. Not every day is green. But soon it will be too late, and everyone will be forced to buy this. Buy what you believe in. Simple. That’s how you succeed in this market

$NNVC - One article I read about this suggests it was 'pneumoic plague' If so - that's caused by a bacterial pathogen named Yersinia pestis. NV-387 would not be effective against that - just standard antibiotics.

$NNVC All the short term vs. long term, bears vs. bulls yap will ultimately be settled by science. Because, at the end of the day, NV-387 will either work or it won’t. The trials are real, administered by some very qualified experts.

$NNVC - Alrighty then! Both Phase 2 trials are now underway. Good luck to us all and to those patients!

$NNVC after each pump, when this corrects, it really corrects, usually to lower lows than when the pump began, learn, listen, sorry newbies.

$NNVC every time this stock goes up you got the penny suckers will sell and make a couple hundred bucks. Will y’all please go somewhere else? 

$NNVC If NV-387 (ORAL GUMMYBEAR vs Refrigerated Remdesivir) proves superior to IV remdesivir... then the fastest path to valuation realization is an outright acquisition by an established infectious disease franchise (such as Gilead, Pfizer, or GSK). Historically, first-in-class approved antiviral platform acquisitions transact in the $1.5B to $3B range... even with Heavy dilution to reach approval... SP could reach $58.00 to $116.00 per share... MONDAY, IMO, we see a POP with the Actual Commencement of Phase II Trials in the CONGO... the heart of EBOLA BREAKOUT!!!

$NNVC If NV-387 proves superior to IV remdesivir, the fastest path to valuation realization is an outright acquisition by an established infectious disease franchise (such as Gilead, Pfizer, or GSK). Historically, first-in-class approved antiviral platform acquisitions transact in the $1.5B to $3B range... even with Heavy dilution to reach approval... SP could reach $58.00 to $116.00 per share...-

$NNVC Playing around with GROK AI and asking questions about a putative Ebola drug trial vs SOC and what would be required for a P value of 0.01 I got these results depending on rate of accrual/mos and efficacy reduction of case fatality rates CFR from the published 67%. Step 4: Time to Reach Statistical Significance Given Accrual Rates If patients are accrued at rates of 10, 20, or 30 per month (total patients, assuming equal randomization): Effect Size Total N Required Time at 10/month Time at 20/month Time at 30/month 25% 352 35.2 months 17.6 months 11.7 months 50% 86 8.6 months 4.3 months 2.9 months 75% 38 3.8 months 1.9 months 1.3 months Based on 90% reduction of CFR the following numbers were generated: Time to Reach Statistical Significance Based on Accrual Rates Accrual Rate (patients/month) Time to accrue 27 patients (months) 10pt/mos 2.7mos 20 1.35 30 0.9 Summary: To detect a 90% reduction in CFR (from 67% to 6.7%) with P=0.01 and 80% power, ~27 patients total (about 14 per group) are required. At an accrual rate of 10 patients/month, the trial would reach statistical significance in about 2.7 months. Faster accrual rates reduce time proportionally. Only time will tell if, and to what degree, effective or not. But, if very effective the time could be dramatically short. And these statistics were using a more stringent P value of 0.01 not 0.05. With a P of0.05 required the numbers are: Time to Reach Statistical Significance Based on Accrual Rates and 90%efficacy Accrual Rate (patients/month) Time to accrue 18 patients (months) 10pt/mos 1.8mos 20 0.9 30 0.6 Thus depending on accrual rate and efficacy the time for the trial to reach degrees of statistical significance could potentially be quite short or much longer if there is only a modest effect on CFR.

$NNVC Nanoviricides presenting at niba's 153rd investment conference in fort lauderdale, fl october 7, 2026

$NNVC announced filing its FY2026 10-K and progress on Phase II NV-387 trials for Mpox and Ebola.